TrialBreast cancer research and treatment2023

A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.

Clinton Yam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.